Skip to content

Author

Adebowale J. Adeniran

We have 3 of 206 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pharmacologic HIF-2α inhibition preserves T cell effector function in clear cell renal cell carcinoma.

Hypoxia-inducible factor 2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC) and a therapeutic target of the small-molecule inhibitor belzutifan. Genetic studies in murine models have suggested that hypoxia signaling may support T cell effector programs, raising concern that HIF-2α inhi...

Katrine N. Madsen, S. Kashima, H. Soulati et al. · 0 citations
Open access Sep 2026

14 Evaluation of the Effects of the HIF-2α Inhibitor Belzutifan on T-cell–Mediated Cytotoxicity in Renal Cell Carcinoma

An in vitro RCC antigen model system was established to evaluate the impact of belzutifan on T-cell cytotoxicity and revealed that IL-2 and IFNG were among the most significantly downregulated genes in HIF2α knockout T cells.

S. Kashima, Katrine N. Madsen, H. Soulati et al. · 0 citations
Open access Sep 2026

51 Discovery of Exhausted CD8+ T-cell States Associated with Clinical Outcomes in Renal Cell Carcinoma

It is found that baseline tumor infiltration by exhausted T cells with a resident memory phenotype (Tex-rm) is significantly associated with worse PFS in advanced RCC patients receiving ICI monotherapy or ICI+TKI combination therapy.

Zhao-Chen Ye, S. Kashima, Rishabh Rout et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.